Company Overview of Affimed N.V.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with g...
Im Neuenheimer Feld 582
Founded in 2000
Key Executives for Affimed N.V.
Chief Executive Officer and Member of Management Board
Total Annual Compensation: €573.0K
Chief Financial Officer and Member of Management Board
Total Annual Compensation: €402.0K
Compensation as of Fiscal Year 2015.
Affimed N.V. Key Developments
Affimed N.V. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017
Jan 19 17
Affimed N.V. Presents at Noble Financial Capital Markets 13th Annual Small Cap and Emerging Growth Investor Conference, Jan-30-2017 . Venue: Boca Raton Resort & Club, 501 E Camino Real, Boca Raton, FL 33432, United States.
Affimed N.V. Provides an Update on its NK-Cell Engager Platform 2016
Jan 11 17
Affimed N.V. provided an update on its NK-cell engager platform. In 2016, the company have significantly expanded activities to optimize the elimination of malignant cells through NK-cell engagement, namely advancing Phase 1b clinical trial of AFM13 in combination with Merck's Keytruda and broadening approach to include the combination of NK-cell engagers with adoptive transfer of activated NK-cells developed at MD Anderson. The company's lead product candidate, AFM13 targeting CD16A on NK-cells and CD30 on tumor cells, is the most advanced NK-cell engager in the clinic. Its development is focused on combination therapy and supported by The Leukemia & Lymphoma Society (LLS). AFM13 is differentiated from monoclonal antibodies as it displays a 1,000-fold higher binding affinity to CD16A, shows very limited competition for NK-cell binding with circulating IgG, as well as higher potency compared to full-length CD30 antibodies. Safety and clinical/pharmacodynamic activity in heavily pretreated Hodgkin lymphoma (HL) patients was established in a Phase 1 study and based on its favorable safety profile and preclinical data, AFM13 is currently under investigation as a combination therapy. Combination therapies have demonstrated improved outcomes for cancer patients and are widely pursued to maximize efficacy of immunotherapeutic approaches. Further broadening the therapeutic opportunities for its NK-cell engagers, Affimed is investigating AFM13 in several combination therapies. Cytokines such as IL-2 or IL-15 boost NK-cell activity and are tested clinically in a variety of cancers. In recent preclinical studies, Affimed demonstrated that AFM13 induced the upregulation of specific interleukin receptors on NK-cells and the subsequent addition of IL-2 or IL-15 had a synergistic effect on AFM13-mediated NK-cell expansion. Hence, the combination of NK-cell engagers with such cytokines may be clinically useful to deepen responses. Affimed is developing AFM13 in combination with the anti-PD-1 antibody Keytruda (pembrolizumab) in relapsed/refractory HL in collaboration with Merck, with Affimed being the study's sole sponsor and Merck supplying Affimed with Keytruda for the trial. The Company has initiated a Phase 1b dose-escalation combination study and safety was determined in the first dose cohort, in which three patients were treated with Keytruda at active dose and AFM13 at 0.5 mg/kg, a level below its active dose when used as single agent. At restaging after 3 months, 2 out of 3 patients had a partial response, which is in line with expectations. With the second dose cohort now fully recruited, Affimed anticipates to provide a further update on the study in the first half of 2017.
Affimed N.V. Presents at BioMed Event by Invest Securities, Jan-26-2017
Jan 5 17
Affimed N.V. Presents at BioMed Event by Invest Securities, Jan-26-2017 . Venue: Salons Hoche, 9 avenue Hoche, 75008 Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 30, 2016